AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 261 min read$DHR

Rothschild & Co Redburn Adjusts Price Target on Danaher to $220 From $205

Rothschild & Co Redburn raised its price target for Danaher to $220 from $205. HSBC also increased its target to $260 from $250. Danaher's stock is currently trading at $230.50, with a 5-day change of +0.33%.

Original reporting
marketscreener.com
Published Oct 26, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$DHR
Bullish
medium confidence
Mentioned
$DHR
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$DHRBullishMed
01

Why it matters

The upward revision may prompt short‑term buying pressure, but the effect depends on broader market sentiment and upcoming earnings.

02

Market read

A modest analyst target increase for a large-cap U.S. stock; modest trading relevance.

03

What to watch

Potential supply‑chain constraints or regulatory risks not reflected in the new target.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Analyst price‑target adjustments are common signals of changing outlooks for a company.

Company-level read

Ticker impact

$DHRBullishMedium confidence
Context

Rothschild & Co Redburn raised Danaher's price target to $220 from $205.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

Target increase reflects improved valuation expectations, which may attract buying interest.

Market effects

Sector

May lift sentiment in the industrial conglomerate sector.

Regional

Limited to U.S. equities where Danaher trades.

Global

Minimal global impact beyond Danaher's shareholder base.

Counterpoint

What could challenge this read

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Company
    Danaher Corp.

    Industrial conglomerate listed on NYSE (ticker DHR).

  • Research Firm
    Rothschild & Co Redburn

    Equity research boutique that issued the target revision.

Read at source← All news

Related articles

OCT 22
$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.

investing.com2 min
OCT 22
$DHRMed

Stifel maintains Buy rating on Danaher, $260 price target

Stifel maintained a Buy rating on Danaher with a $260 price target, suggesting 11.2% upside from the Oct 21 close. The firm cited strong financial performance, including 8.5% revenue growth and a 29.0% adjusted operating profit margin, as well as positive growth prospects under new leadership.

tradingview.com1 min
OCT 22
$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

finance.yahoo.com1 min
OCT 22
$DHRHighAI 9/10

DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook

Danaher (DHR) reported Q3 revenue of $6.55B, matching estimates, and adjusted EPS of $2.11, beating forecasts. The company raised its full-year EPS guidance to $8.59. Organic revenue grew 3%, driven by strong demand in bioprocessing and diagnostics. Management highlighted AI strategy, M&A integration, and market recovery trends. Risks include variability in respiratory-related revenue and bioprocessing projects.

finance.yahoo.com2 min